{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:07:53Z","timestamp":1791216473982,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007659","name":"Bayer HealthCare Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000801","name":"Bayer HealthCare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.euo.2025.10.001","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T03:53:59Z","timestamp":1762314839000},"page":"555-562","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Age-related Efficacy and Safety of Darolutamide Plus Androgen-deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-sensitive Prostate Cancer: A Subgroup Analysis of the Phase 3 ARASENS Trial"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9983-5934","authenticated-orcid":false,"given":"Joan","family":"Carles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Tombal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Fizazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"Montesa Pino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jos\u00e9","family":"M\u00e9ndez-Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejo","family":"Rodriguez-Vida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Castellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Borrega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Adorjan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Moretones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjari","family":"Dissanayake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2025.10.001_b0005","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.euo.2025.10.001_b0010","article-title":"Management of prostate cancer in older adults","volume":"43","author":"Graham","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.euo.2025.10.001_b0015","doi-asserted-by":"crossref","first-page":"397.e9","DOI":"10.1016\/j.urolonc.2025.01.001","article-title":"Association between frailty and specific comorbidities on oncological outcomes in metastatic hormone-sensitive and castration resistant prostate cancer","volume":"43","author":"Wenzel","year":"2025","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2025.10.001_b0020","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ejca.2019.04.031","article-title":"Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients","volume":"116","author":"Boyle","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.euo.2025.10.001_b0025","unstructured":"Cornford P, Tilki D, van den Bergh RCN, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. https:\/\/uroweb.org\/guideline\/prostate-cancer\/."},{"key":"10.1016\/j.euo.2025.10.001_b0030","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1097\/JU.0000000000003452","article-title":"Updates to advanced prostate cancer: AUA\/SUO guideline (2023)","volume":"209","author":"Lowrance","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.10.001_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115335","article-title":"Are evidence-based guidelines translating into clinical practice? A national population-based study of the use of treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC) in England","volume":"220","author":"Dodkins","year":"2025","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.euo.2025.10.001_b0040","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/bju.16577","article-title":"Real-world use of androgen-deprivation therapy intensification for metastatic hormone-sensitive prostate cancer: a systematic review","volume":"135","author":"Raval","year":"2025","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2025.10.001_b0045","first-page":"e25","article-title":"Practice patterns and predictors of treatment intensification in patients with metastatic castration-sensitive prostate cancer","volume":"19","author":"Gotto","year":"2025","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.euo.2025.10.001_b0050","doi-asserted-by":"crossref","first-page":"12007","DOI":"10.1038\/srep12007","article-title":"Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies","volume":"5","author":"Moilanen","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.euo.2025.10.001_b0055","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s11523-019-00674-0","article-title":"Evaluation of clinically relevant drug-drug interactions and population pharmacokinetics of darolutamide in patients with nonmetastatic castration-resistant prostate cancer: results of pre-specified and post hoc analyses of the phase III ARAMIS trial","volume":"14","author":"Shore","year":"2019","journal-title":"Target Oncol"},{"key":"10.1016\/j.euo.2025.10.001_b0060","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s11523-023-00959-5","article-title":"Comparison of cerebral blood flow in regions relevant to cognition after enzalutamide, darolutamide, and placebo in healthy volunteers: a randomized crossover trial","volume":"18","author":"Williams","year":"2023","journal-title":"Target Oncol"},{"key":"10.1016\/j.euo.2025.10.001_b0065","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s13318-019-00577-5","article-title":"Drug-drug interaction potential of darolutamide: in vitro and clinical studies","volume":"44","author":"Zurth","year":"2019","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.euo.2025.10.001_b0070","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1200\/JCO.2019.37.7_suppl.156","article-title":"Higher blood\u2013brain barrier penetration of [14C]apalutamide and [14C]enzalutamide compared to [14C]darolutamide in rats using whole-body autoradiography","volume":"37","author":"Zurth","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.10.001_b0075","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.10.001_b0080","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2217\/ahe.09.31","article-title":"Bone marrow, thymus and blood: changes across the lifespan","volume":"5","author":"Prabhakar","year":"2009","journal-title":"Aging Health"},{"key":"10.1016\/j.euo.2025.10.001_b0085","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1200\/JCO.23.00041","article-title":"Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS trial","volume":"41","author":"Hussain","year":"2023","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"10.1016\/j.euo.2025.10.001_b0090","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/JCO.2025.43.5_suppl.20","article-title":"Which patients with metastatic hormone-sensitive prostate cancer (mHSPC) benefit more from androgen receptor pathway inhibitors (ARPIs)? STOPCAP meta-analyses of individual participant data (IPD)","volume":"43","author":"Fisher","year":"2025","journal-title":"J Clin Oncol"},{"issue":"Suppl 6","key":"10.1016\/j.euo.2025.10.001_b0095","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/JCO.2023.41.6_suppl.20","article-title":"Efficacy and safety of abiraterone acetate plus prednisone and ADT +\/- docetaxel in older patients (\u226570 years), with de novo mCSPC, compared to younger patients (<70 years): the PEACE-1 trial","volume":"41","author":"Mourey","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.10.001_b0100","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/s41391-024-00886-0","article-title":"Cardiovascular events among men with prostate cancer treated with androgen receptor signaling inhibitors: a systematic review, meta-analysis, and network meta-analysis","volume":"28","author":"Matsukawa","year":"2025","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euo.2025.10.001_b0105","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.eururo.2019.07.031","article-title":"Mortality and hospitalization risk following oral androgen signaling inhibitors among men with advanced prostate cancer by pre-existing cardiovascular comorbidities","volume":"77","author":"Lu-Yao","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.10.001_b0110","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.eururo.2024.08.031","article-title":"Prostate Cancer Therapy Cardiotoxicity Map (PROXMAP) for advanced disease states: a systematic review and network meta-analysis with Bayesian modeling of treatment histories","volume":"87","author":"Aziz","year":"2025","journal-title":"Eur Urol"},{"issue":"Suppl","key":"10.1016\/j.euo.2025.10.001_b0115","doi-asserted-by":"crossref","first-page":"S968","DOI":"10.1016\/j.annonc.2023.09.2742","article-title":"1792P Effects of enzalutamide on overall survival +\/- early docetaxel in participants aged less than 70 yrs versus greater than or equal to 70 yrs in ENZAMET (ANZUP 1304)","volume":"34","author":"Horvath","year":"2023","journal-title":"Ann Oncol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258893112500255X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258893112500255X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T20:41:08Z","timestamp":1785184868000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S258893112500255X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S258893112500255X"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2025.10.001","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Age-related Efficacy and Safety of Darolutamide Plus Androgen-deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-sensitive Prostate Cancer: A Subgroup Analysis of the Phase 3 ARASENS Trial","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2025.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}